Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
September 12, 2023 08:00 ET
|
Spinogenix, Inc.
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced a second...
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
September 12, 2023 06:30 ET
|
ZyVersa Therapeutics
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic lateral sclerosis (“ALS”)This study showed that NLRP3...
Autism: Is This a Vascular Disease and Would Therapeutic Angiogenesis Be a Potential Treatment?
August 15, 2023 08:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Dr. Jack Jacobs, Chief Science Officer of Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), will be presenting at the online AutismOne...
AC Immune SA Appoints New Chief Medical Officer
July 26, 2023 07:00 ET
|
AC Immune SA
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:...
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
July 03, 2023 07:00 ET
|
AC Immune SA
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...
AC Immune Holds Annual General Meeting of Shareholders
June 23, 2023 16:30 ET
|
AC Immune SA
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ:...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
April 28, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease...
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
April 24, 2023 07:30 ET
|
ProMIS Neurosciences Inc.
Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrated selective binding and protection against toxic amyloid-beta oligomersPreclinical data support misfolded RACK1 as a potential...
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
April 05, 2023 07:00 ET
|
AC Immune SA
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST Lausanne,...
Astex and Cardiff University Medicines Discovery Institute Announce New Drug Discovery Collaboration on Neurodegenerative Diseases
February 13, 2023 04:00 ET
|
Astex Pharmaceuticals
CAMBRIDGE and CARDIFF, United Kingdom, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small...